vs
Mid-America Apartment Communities（MAA）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $555.6M、Mid-America Apartment Communitiesの約1.4倍）。Revvityの純利益率が高く（12.7% vs 10.4%、差は2.4%）。Revvityの前年同期比売上増加率が高い（5.9% vs 1.0%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $158.6M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs 1.1%）
Mid-America Apartment Communities, Inc.（証券コード：MAA）はテネシー州メンフィスに本社を置く上場不動産投資信託（REIT）で、主に米国南東部・南西部の集合住宅物件への投資を事業の中核とし、成長性の高い地域の住宅不動産分野で事業を展開し、株主に安定した投資リターンをもたらすことを目指しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
MAA vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $555.6M | $772.1M |
| 純利益 | $57.6M | $98.4M |
| 粗利率 | — | — |
| 営業利益率 | 10.4% | 14.5% |
| 純利益率 | 10.4% | 12.7% |
| 売上前年比 | 1.0% | 5.9% |
| 純利益前年比 | -65.5% | 3.9% |
| EPS（希薄化後） | $0.48 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $555.6M | $772.1M | ||
| Q3 25 | $554.4M | $698.9M | ||
| Q2 25 | $549.9M | $720.3M | ||
| Q1 25 | $549.3M | $664.8M | ||
| Q4 24 | $549.8M | $729.4M | ||
| Q3 24 | $551.1M | $684.0M | ||
| Q2 24 | $546.4M | $691.7M | ||
| Q1 24 | $543.6M | $649.9M |
| Q4 25 | $57.6M | $98.4M | ||
| Q3 25 | $99.5M | $46.7M | ||
| Q2 25 | $108.1M | $53.9M | ||
| Q1 25 | $181.7M | $42.2M | ||
| Q4 24 | $166.6M | $94.6M | ||
| Q3 24 | $115.2M | $94.4M | ||
| Q2 24 | $102.0M | $55.4M | ||
| Q1 24 | $143.7M | $26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
| Q4 25 | 10.4% | 14.5% | ||
| Q3 25 | 18.7% | 11.7% | ||
| Q2 25 | 20.2% | 12.6% | ||
| Q1 25 | 34.0% | 10.9% | ||
| Q4 24 | 31.3% | 16.3% | ||
| Q3 24 | 21.5% | 14.3% | ||
| Q2 24 | 19.3% | 12.4% | ||
| Q1 24 | 27.4% | 6.8% |
| Q4 25 | 10.4% | 12.7% | ||
| Q3 25 | 18.0% | 6.7% | ||
| Q2 25 | 19.7% | 7.5% | ||
| Q1 25 | 33.1% | 6.4% | ||
| Q4 24 | 30.3% | 13.0% | ||
| Q3 24 | 20.9% | 13.8% | ||
| Q2 24 | 18.7% | 8.0% | ||
| Q1 24 | 26.4% | 4.0% |
| Q4 25 | $0.48 | $0.86 | ||
| Q3 25 | $0.84 | $0.40 | ||
| Q2 25 | $0.92 | $0.46 | ||
| Q1 25 | $1.54 | $0.35 | ||
| Q4 24 | $1.43 | $0.77 | ||
| Q3 24 | $0.98 | $0.77 | ||
| Q2 24 | $0.86 | $0.45 | ||
| Q1 24 | $1.22 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $60.3M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $5.7B | $7.3B |
| 総資産 | $12.0B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $60.3M | $919.9M | ||
| Q3 25 | $32.2M | $931.4M | ||
| Q2 25 | $54.5M | $991.8M | ||
| Q1 25 | $55.8M | $1.1B | ||
| Q4 24 | $43.0M | $1.2B | ||
| Q3 24 | $50.2M | $1.2B | ||
| Q2 24 | $62.8M | $2.0B | ||
| Q1 24 | $54.6M | $1.7B |
| Q4 25 | $5.7B | $7.3B | ||
| Q3 25 | $5.8B | $7.4B | ||
| Q2 25 | $5.9B | $7.6B | ||
| Q1 25 | $5.9B | $7.6B | ||
| Q4 24 | $5.9B | $7.7B | ||
| Q3 24 | $5.9B | $7.9B | ||
| Q2 24 | $6.0B | $7.9B | ||
| Q1 24 | $6.1B | $7.8B |
| Q4 25 | $12.0B | $12.2B | ||
| Q3 25 | $11.9B | $12.1B | ||
| Q2 25 | $11.8B | $12.4B | ||
| Q1 25 | $11.8B | $12.4B | ||
| Q4 24 | $11.8B | $12.4B | ||
| Q3 24 | $11.8B | $12.8B | ||
| Q2 24 | $11.6B | $13.4B | ||
| Q1 24 | $11.5B | $13.4B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $261.7M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $158.6M | $161.8M |
| FCFマージンFCF / 売上 | 28.5% | 21.0% |
| 設備投資強度設備投資 / 売上 | 18.6% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 4.55× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $717.9M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $261.7M | $182.0M | ||
| Q3 25 | $266.4M | $138.5M | ||
| Q2 25 | $353.4M | $134.3M | ||
| Q1 25 | $196.6M | $128.2M | ||
| Q4 24 | $239.1M | $174.2M | ||
| Q3 24 | $309.5M | $147.9M | ||
| Q2 24 | $349.4M | $158.6M | ||
| Q1 24 | $200.3M | $147.6M |
| Q4 25 | $158.6M | $161.8M | ||
| Q3 25 | $170.8M | $120.0M | ||
| Q2 25 | $264.5M | $115.5M | ||
| Q1 25 | $124.0M | $112.2M | ||
| Q4 24 | $152.6M | $149.8M | ||
| Q3 24 | $215.5M | $125.6M | ||
| Q2 24 | $259.7M | $136.6M | ||
| Q1 24 | $148.2M | $129.7M |
| Q4 25 | 28.5% | 21.0% | ||
| Q3 25 | 30.8% | 17.2% | ||
| Q2 25 | 48.1% | 16.0% | ||
| Q1 25 | 22.6% | 16.9% | ||
| Q4 24 | 27.8% | 20.5% | ||
| Q3 24 | 39.1% | 18.4% | ||
| Q2 24 | 47.5% | 19.7% | ||
| Q1 24 | 27.3% | 20.0% |
| Q4 25 | 18.6% | 2.6% | ||
| Q3 25 | 17.2% | 2.6% | ||
| Q2 25 | 16.2% | 2.6% | ||
| Q1 25 | 13.2% | 2.4% | ||
| Q4 24 | 15.7% | 3.4% | ||
| Q3 24 | 17.1% | 3.3% | ||
| Q2 24 | 16.4% | 3.2% | ||
| Q1 24 | 9.6% | 2.7% |
| Q4 25 | 4.55× | 1.85× | ||
| Q3 25 | 2.68× | 2.97× | ||
| Q2 25 | 3.27× | 2.49× | ||
| Q1 25 | 1.08× | 3.03× | ||
| Q4 24 | 1.43× | 1.84× | ||
| Q3 24 | 2.69× | 1.57× | ||
| Q2 24 | 3.43× | 2.87× | ||
| Q1 24 | 1.39× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MAA
| Same Store | $515.5M | 93% |
| Non Same Store And Other | $36.8M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
